IISc Bangalore, Bharat Serums and Vaccines ink pact for research on Next-Gen Snakebite Therapy - Video
Overview
Bharat Serums and Vaccines Ltd. (BSV), a biopharmaceutical company in India, has announced a meaningful collaboration with the 'Evolutionary Venomics Lab', at the Indian Institute of Science (IISc) Bangalore to develop region-specific antivenoms, thereby, pioneering next-generation snakebite therapy in India.
Snakebite remains a serious public health challenge. Currently, treatments are based on a single polyvalent antivenom designed for snakebites from the 'big four' snakes in the country. Recent research at the Evolutionary Venomics Lab has highlighted the alarming consequence of the inter and intra-species variation in venoms on the effectiveness of antivenom. The polyvalent antivenom inefficaciously neutralizes the venom from distinct populations of the 'big four' snakes, as well many other local clinically important snake species. Thus, there is an urgent need for the development of region-specific antivenom in the country.
For more news, check out the Medical Dialogues:
Speakers
